Predictive Technology Group, Inc. (PRED) Reaches Key Clinical Milestone in Development of Genetic Tests for Infertility and Endometriosis

Development of ARTGuide® Test Will Rapidly Accelerate Short-Term Company Growth

Salt Lake City, UT — (January 18, 2017) – Predictive Therapeutics, LLC, a wholly owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, was formally notified by its research and development partner, Juneau Biosciences, LLC that a key product development milestone has been reached — the sensitivity and specificity of the ARTGuide® predictive test has passed a critical clinical threshold.  Details of this achievement will remain confidential until a scheduled scientific presentation at the upcoming World Congress of Endometriosis to be held in Vancouver, Canada in May 2017.  Predictive Therapeutics will continue to provide development and financial support to Juneau to allow final validation of these “Laboratory Developed Tests” (LDTs) under “Clinical Laboratory Improvement Amendments” (CLIA) guidelines

In 2016, Predictive Therapeutics signed a license agreement with Juneau Biosciences, LLC for the commercialization of assays and related services for the prediction of Endometriosis, and other health concerns, in the infertility market. This license extends the close relationship between the two companies.

Given these developments, Predictive Therapeutics and Juneau are now poised to launch their novel test for women experiencing infertility, called ARTGuide®. The ARTGuide® Test is expected to change the way that Advanced Reproductive Technologies (ART) such as In Vitro Fertilization (IVF) is used to help couples struggling to have a baby.  The commercial launch of the ARTGuide® infertility test in the United States is now expected during Q3 2017.

Bradley Robinson, PRED CEO states, “I am quite certain that the ARTGuide® Test has the potential to increase the likelihood that couples struggling with infertility will be more successful at becoming pregnant, which could dramatically transform this lucrative infertility market.  The ARTGuide® Test will provide ‘must-have’ information for affected couples and their physicians.

About Endometriosis:

Endometriosis affects more than 10 million women in the United States.  Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis.  Monthly bleeding and inflammation caused by these lesions may severely impact a woman’s quality of life.  Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women with endometriosis suffer for over a decade before receiving treatment.  Treatment may involve hormonal suppression or the targeted destruction of the abnormal tissue during surgery.

About Juneau Biosciences:

Juneau Biosciences is a privately held medical genetics company conducting groundbreaking research to develop innovative diagnostic products for diseases that predominantly affect women. Launched in early 2007, the Salt Lake City, Utah-based firm has focused so far on the development of novel molecular diagnostics and therapeutics for endometriosis, a condition estimated to affect approximately 10% of reproductive-age females. This research is the basis of all the tests and therapies that we will produce, patent, and disseminate to signal the revolution in women’s health care. 
 Over the next several years, Juneau will launch additional programs for preterm labor and other gynecological and obstetric disorders. Juneau expects to improve the lives of millions of women through our genetic research and innovative health care solutions. 

Juneau Biosciences’ knowledgeable team, state-of-the-art facilities, and innovative research techniques give us a unique advantage in developing diagnostics and treatments for women. 

About Predictive Technology Group, Inc.:

Predictive Technology Group, Inc. ( PRED ), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about the release contact, Mr. Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.predictivetechnologygroup.com, www.predrx.com, and www.yesinternational.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

 

Predictive Technology Group, Inc. (PRED) Announces US Patent for Method for Performing an Advanced Reproductive Therapy Supporting Licensed Technology from Juneau Biosciences

Acquisition Strengthens Commercialization Strategy of Company’s Gene Therapy Products

Salt Lake City, UT — (January 12, 2017) – Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announces the issuance of US patent 9,434,991 direct to a method for performing an Advanced Reproductive Therapy (“ART”).

The Centers for Disease Control and Prevention (”CDC”) estimates 208,604 ART cycles were performed in 2014 resulting in 70,354 live births in the United States in 2014. Mike Schramm, PRED’s Director of Intellectual Property, described the claims of 9,434,991 as covering any in vitro fertility treatment of an egg of a woman having any gynecological disorder associated biomarker.

“The issuance of this US patent significantly strengthens PRED’s Intellectual Property position and mission of assisting parents in delivering the healthiest babies possible,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The rights to this technology are seen as a synergistic companion to our medicinal therapeutic products.”

According to Technavio’s latest report, the global fertility services market is expected to exceed USD 21 billion by 2020, growing at a CAGR of almost 9% during the forecast period.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL at 757-306-6090, yes@yesinternational.com, www.predictivetechnologygroup.com, www.predrx.com, and www.yesinternational.com.

 Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

Northstar Electronics Recap of Main Events of 2016

Virginia Beach, VA, Jan. 10, 2017 (GLOBE NEWSWIRE) — Northstar Electronics, Inc.(NEIK:OTCQB), the “Company”,  provides a Recap of the main events of 2016.

To summarize, the Company’s primary objectives for 2016 were two fold. One was to improve the Company’s standing as a publicly traded platform. The second was to make significant progress for the Company’s subsidiary, Northstar Sealand Enterprises Ltd. (NSEL), to secure the exclusive worldwide ownership rights to the enhanced version of a single engine Turbo-Prop industrial airplane owned by the subsidiary of a major international aerospace company. NSEL intends to manufacture, market and sell the airplane and also carry out Maintenance, Repair and Overhaul (MRO) services.

During the year, the Company achieved its goals of becoming current with its SEC filings and returning to the OTCQB trading platform, actions fundamental to the Company’s future success.

With respect to the acquisition of the rights to the airplane, significant progress was made on key matters. Agreement with the aerospace company subsidiary was reached during the year on the main technical issues. As well, strong progress was made on project scheduling and cost estimates.

At year’s end, NSEL and the aerospace company subsidiary signed a milestone Memorandum of Understanding (MOU). The MOU outlines the key actions and goals to be reached in order for both parties to implement their business plans going forward. The signing of this MOU is a major step which ultimately should lead to NSEL reaching its manufacturing and marketing objectives within a reasonable time frame.

GOALS FOR 2017

The Company’s goals for NSEL in 2017 are to finalize the acquisition of the exclusive worldwide rights to the Turbo Prop industrial airplane and initiate the transfer of the Type Certificate to NSEL, to initiate the establishment of first order technical support, to put in place a Supply Chain Management system, to initiate the marketing campaign and to secure the first sales orders for the airplane.

We will be approaching institutional investors and venture capital companies for the funding needed to grow the company. As well, we will explore funding opportunities through certain government support programs.

About Northstar Electronics, Inc.

Northstar was established in the late 1990’s. The Company has carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts Northstar has been seeking other strategic relationships

Safe Harbor Statement:

This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

For further information about this news release contact:

Rich Kaiser, Investor Relations, Yes International, 757-306-6090, yes@yesinternational.com

Predictive Technology Group, Inc. (PRED) Announces Acquisition of US Patent Application for Method for Treating Patients with Stem Cells “Cleaned” via CRISPR

Acquisition Strengthens Commercialization Strategy of Company’s Gene Therapy Products

Salt Lake City, UT — January 10, 2017 – Predictive Technology Group, Inc. (OTCPINK: PRED), a life sciences technology holding company, announced the acquisition of US patent application 62/295,042 direct to the practice of “cleaning” stem cells of a predetermined disease-associated marker via theClustered Regularly Interspaced Short Palindromic Repeats CRISPR” process and administering the stem cells to the patient.

“Clustered Regularly Interspaced Short Palindromic Repeats” (CRISPR) technology offers several advantages over previous forms of gene-editing. The human cell’s genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. Unlike other current practices which involve the introduction of foreign DNA.

“The claims are drawn to the ’cleaning‘ of any stem cell having a predetermined disease associated biomarker,” said Mike Schramm, PRED’s Director of Intellectual Property.  “Because the patent application is for both autologous (withdrawn from and reintroduced to the same patient) and homologous (derived from another source), we see very broad use of the application.”

These rights enable PRED to both diagnose a patient for a genetic disease based on a specific biomarker and subsequently treating the patient with their own stem cells having the diagnosed biomarker eliminated via the CRISPR method.

“This is a significant opportunity for our company to obtain the rights to this invention,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The technology is a strong bridge between our Molecular Diagnostic and Regenerative Medicine product portfolios.”

The global genome editing market is expected to reach USD $5.54 Billion by 2021 from USD $2.84 Billion in 2016, growing at a CAGR of 14.3%. (Source: Market and Market 2016 Genome Editing and Genome Engineering Report)

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com and www.predictivetechnologygroup.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) ANNOUNCES NEW PRESIDENT/CEO /CHAIRMAN

Virginia Beach, VA- January 3, 2017- BioForce Nanosciences Holdings, Inc. (BFNH.OTCPINK) announces Mr. Merle Ferguson as its new President/ CEO / Chairman.  Mr. Ferguson brings to BFNH business acumen from both the public and private business arenas.

Further, BioForce Nanosciences Holdings, Inc.’s business focuses on the acquisition of services, productions, and agricultural facilities within the food services sector.

For further information about this release, contact YES INTERNATIONAL, Investor Relations, 757-306-6090, yes@yesinternational.com and www.yesinternational.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.